Compare FNKO & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNKO | SENS |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.8M | 301.2M |
| IPO Year | 2017 | 2014 |
| Metric | FNKO | SENS |
|---|---|---|
| Price | $5.40 | $6.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.00 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 583.4K | 525.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $908,209,000.00 | $16,389,000.00 |
| Revenue This Year | $4.42 | $74.15 |
| Revenue Next Year | $6.50 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $2.22 | $0.41 |
| 52 Week High | $6.09 | $8.75 |
| Indicator | FNKO | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 57.27 | 50.35 |
| Support Level | $2.92 | $6.40 |
| Resistance Level | $5.73 | $6.87 |
| Average True Range (ATR) | 0.28 | 0.49 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 74.79 | 23.31 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.